Sales 20% and EBIT adj. 34% vs. ABGSCe Strong quarter with record turnover Set to enter next phase o...
Redeye’s long-term view of Dignitana is, to a degree, intact, even if the sales progression has been...
Gapwaves carried over its momentum from Q1 into the Q2 report, beating Redeye's estimates and consen...
Redeye updates on Better Collective following its Q2-results which were in line with our expectation...
First Venture publicerade den 22 augusti 2024 bolagets delårsrapport för det andra kvartalet av 2024...
Sales +4%, adj. EBITA -4% vs. cons, +5% org. sales Cons to lower '24e adj.
Redeye updates on Northbaze following its Q2 results, which were stronger than expected in both sale...
Redeye comments on Medivir's Q2 report. The main event in the quarter was the presentation of an est...
Redeye updates its estimates following Surgical Science’s Q2 2024 report, which featured a sequentia...
Redeye provides an update following SenzaGen’s Q2 2024 report.
26% organic sales growth y-o-y Growth initiatives hurt profitability mid-term Pricing to act as a ta...
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) redovisar en minskad nettoomsättn...
Updating estimates after full release of H1 numbers More guidance upgrades possible + M&A increasing...
Nettoomsättningen för det andra kvartalet uppgick till 10,2 MEURO (9,5), vilket motsvarade en ökning...
Redeye comments on Nekkar’s H1’24 report that posted mixed results, with continued revenue growth in...
Redeye comments on Enviro’s Q2 report, which held no surprises.
Net sales were 9% lower than our estimate. Costs were in line with our expectations, which led to lo...
Industribolaget AGES Industri presenterade en rapport för det andra kvartalet som var något svagare ...
Redeye provides a research update following the Q2 report published by Alzinova earlier today.
Revenues and EBIT 2 and 14% ahead of expectations Order intake of DKK 2.
